Forxiga dapagliflozin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Dec. 12 to discuss a resubmitted NDA from Bristol-Myers for Forxiga dapagliflozin to treat Type II diabetes. The PDUFA date is ...